Latest Biotechnology, Pharmaceutical and Healthcare News from Net Resources International

03:35 EDT 23rd September 2017 | BioPortfolio

Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.

More Information about Net Resources International on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.

Showing News Articles 1–25 of 2,300+ from Net Resources International

Thursday 21st September 2017

Shire reports positive data from Phase III trial of Intuniv for ADHD

Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial of Intuniv (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder (…

Audentes commences dosing in Phase I/II trial for myotubular myopathy

US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate AT132 to treat X-linked myotubular myopathy (XLMTM).

Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma

Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

Wednesday 20th September 2017

AgeneBio to study AGB101 in Phase III trial to treat MCI due to AD

US-based pharmaceutical firm AgeneBio is set to investigate its therapeutic agent AGB101 in a Phase III clinical trial (HOPE4MCI) for the treatment of mild cognitive impairment due to Alzheimer’s disease (MCI due to AD).

Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer

The Parker Institute for Cancer Immunotherapy and Cancer Research Institute in the US have started dosing patients in a Phase Ib/II clinical trial to investigate the combination of standard chemotherapy and immunotherapy for the treatment of pancreat…

Transgene starts dosing in Phase Ib/II combination trial for HPV-positive cancers

Transgene has started dosing patients in a Phase Ib/II clinical trial of TG4001 in combination with avelumab to treat human papillomavirus type 16 positive (HPV-16+) recurrent or metastatic cancers.

Pharmaceutical Development Group-Pharmaceutical Regulatory Consultant and FDA Regulatory Strategist

Pharmaceutical Development Group (PDG) provides pharmaceutical regulatory consulting to firms located around the world.

Tuesday 19th September 2017

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL

US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL).

Janssen reports positive long-term Phase III data of Tremfya for plaque psoriasis

Janssen Research & Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya (Guselkumab) to treat moderate-to-severe plaque psoriasis.

Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial

Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure treatment.

Monday 18th September 2017

Sanofi and Regeneron report positive Phase III data from atopic dermatitis trial

Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase III clinical trial (CAFÉ) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis (AD).

Australian cancer centres launch personalised medicine trial for childhood cancers

Cancer centres in Australia have launched a national clinical trial under the Zero Childhood Cancer programme to evaluate personalised medicine for childhood cancers.

Inovio launches Phase I/IIa trial for MERS infection in South Korea

US-based immunotherapy firm Inovio Pharmaceuticals has launched a Phase I/IIa clinical trial of its vaccine candidate GLS-5300 to treat MERS (Middle East Respiratory Syndrome) infection in South Korea.

Sunday 17th September 2017

Phrixus to study P-188 NF in Phase II trial to treat DMD

US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD).

Novo Nordisk’s Tresiba minimises hypoglycaemia rate in diabetes trial

Denmark-based pharmaceutical firm Novo Nordisk has reported positive results from a clinical trial (DEVOTE) of Tresiba (insulin degludec) to treat patients with type 2 diabetes.

TG Therapeutics commences enrolment for Phase III multiple sclerosis trials

US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme of TG-1101 (ublituximab) to treat patients with relapsing multiple sclerosis (RMS).

Thursday 14th September 2017

Pfizer and Astellas report positive Phase III data from prostate cancer trial

Pfizer and Astellas Pharma have reported positive results from a Phase III clinical trial (PROSPER) of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) to treat patients with non-metastatic (M0) castration-resistant prosta…

M&As this week: inviCRO, Inotek Pharmaceuticals Corporation

inviCRO has completed the acquisition of UK-based translational research company Imanova.

Deals this week: Synthetic Biologics, Bayer, HitGen

Synthetic Biologics has raised $12m through the private placement of 120,000 series A preferred shares priced at $100 a share.

Tulane University reports favourable results from new malaria trial

Tulane University in the US has reported positive results from a clinical trial of its new drug AQ-13, which is being developed for the treatment of malaria.

Wednesday 13th September 2017

Dyanamic Light Scattering - Common Terms Defined

There are a number of sources of information that give a mathematical description of the terms used in light scattering. However, these will not usually give assistance in understanding their practical application.

GSK reports positive Phase III results of mepolizumab for COPD

GlaxoSmithKline (GSK) has reported positive results from two Phase III clinical trials of mepolizumab to treat patients with eosinophilic chronic obstructive pulmonary disease (COPD).

Menarini and OBT conduct Phase I oncology trial of MEN1309

Italian pharmaceutical company Menarini Ricerche has partnered with UK-based biotechnology firm Oxford BioTherapeutics (OBT) to conduct a Phase I clinical trial of MEN1309 to treat patients with metastatic solid cancers and non-Hodgkin’s lymphoma (NH…

OncoMed begins dosing GITRL-Fc in Phase Ia trial for solid tumours

US-based OncoMed Pharmaceuticals has begun dosing patients in a Phase Ia clinical trial of its therapeutic candidate GITRL-Fc (OMP-336B11) to treat patients suffering from solid tumours.

Quick Search

News Quicklinks